Q1: 2026-05-13 Earnings Abstract
EPS of -$0.18 beats by $0.00
| Income of $0.00 misses by $1,820.00
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Name Could 13, 2026 5:00 PM EDT
Firm Contributors
Christine Cassiano – Govt VP, Chief Company Affairs & Model Technique Officer
David Chang – Co-Founder, President, CEO & Director
Zachary Roberts – Govt VP of Analysis & Growth and Chief Medical Officer
Geoffrey Parker – Govt VP & CFO
Convention Name Contributors
Michael Yee – UBS Funding Financial institution, Analysis Division
Tyler Van Buren – TD Cowen, Analysis Division
Biren Amin – Piper Sandler & Co., Analysis Division
Salveen Richter – Goldman Sachs Group, Inc., Analysis Division
Samantha Semenkow – Citigroup Inc., Analysis Division
Matthew Phipps – William Blair & Firm L.L.C., Analysis Division
Jack Allen – Robert W. Baird & Co. Included, Analysis Division
John Newman – Canaccord Genuity Corp., Analysis Division
Reni Benjamin – Residents JMP Securities, LLC, Analysis Division
Lut Ming Cheng – JPMorgan Chase & Co, Analysis Division
Presentation
Operator
Howdy. Thanks for standing by, and welcome to Allogene Therapeutics First Quarter 2026 Convention Name. [Operator Instructions] Please bear in mind that at the moment’s convention name is being recorded.
I might now like to show the decision over to Christine Cassiano, Chief Company Affairs and Model Technique Officer.
Ms. Cassiano, please go forward.
Christine Cassiano
Govt VP, Chief Company Affairs & Model Technique Officer
Thanks, operator, and welcome, everybody, to Allogene’s convention name. After the market closed, Allogene issued a press launch that supplied a enterprise replace and monetary outcomes for the primary quarter of 2026. This press launch and at the moment’s webcast can be found on our web site.
Following our ready remarks, we are going to host a Q&A session and we are going to purpose to maintain the decision to below an hour. I am joined at the moment by Dr. David Chang, President and Chief Govt Officer; Dr. Zachary Roberts, Govt Vice President of Analysis and Growth and Chief Medical Officer; and Geoff Parker, Chief Monetary Officer.
